Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Gastroenterol
Glavni autori: Ikeda, Kenji, Kudo, Masatoshi, Kawazoe, Seiji, Osaki, Yukio, Ikeda, Masafumi, Okusaka, Takuji, Tamai, Toshiyuki, Suzuki, Takuya, Hisai, Takashi, Hayato, Seiichi, Okita, Kiwamu, Kumada, Hiromitsu
Format: Artigo
Jezik:Inglês
Izdano: Springer Japan 2016
Teme:
Original Article—Liver, Pancreas, and Biliary Tract
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5357473/
https://ncbi.nlm.nih.gov/pubmed/27704266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-016-1263-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items